Zhilin Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhilin Yu has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
Xin Liu
Key Laboratory of Functional Polymer Materials, Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Institute of Polymer Chemistry, College of Chemistry, Nankai University, Tianjin, China
16 shared publicationsZeyu Zhang
Nankai University 94 Weijin Road
16 shared publicationsBinbin Hu
Tianjin Key Laboratory of Biosensing and Molecular Recognition, Research Center for Analytical Science, Frontiers Science Center for New Organic Matter, College of Chemistry, Nankai University, Tianjin, China
15 shared publicationsNa Song
Key Laboratory of Functional Polymer Materials, Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Institute of Polymer Chemistry, College of Chemistry
12 shared publicationsHao Wang
Key Laboratory of Functional Polymer Materials, Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Institute of Polymer Chemistry, College of Chemistry, Nankai University, Tianjin, China
10 shared publications- Linqi Shi
State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Functional Polymer Materials, Ministry of Education, Institute of Polymer Chemistry, College of Chemistry, Nankai University, Tianjin 300350, PR China
10 shared publications
Latest Publications
- 16 November 2026
- Published by Elsevier in Nano Today
- Vol. 72
Nonconventional membrane lytic peptide-based antibacterial nanomaterials
- 16 November 2026
- Published by Elsevier in Nano Today
- Vol. 72
Nonconventional membrane lytic peptide-based antibacterial nanomaterials
- Open Access
- 5 November 2026
- Published by Wiley in Angewandte Chemie
Self‐Assembled Macrocyclic Nanocarriers for Rapid Ratiometric Loading and Dosing of Multidrug Combinations
Screening optimal drug combinations and dosing ratios is crucial for achieving and maximizing the synergistic therapeutic benefits in combined treatments. Traditional drug loading methods lack the precision to control drug ratios or involve complex technologies, failing to meet the demands of large‐scale screening in accuracy, convenience, and applicability. To address this, we developed a thermodynamically programmable macrocyclic nanoplatform based on amphiphilic calixarenes that overcomes the kinetic limitations on drug loading accuracy and reproducibility. This platform achieved precise drug loading and release with convenient tunability and broad‐spectrum applicability. For a series of drugs across various ratios, the actual loading ratio is > 95% consistent with the assigned values, and the consistency in delivery into cells and tumor tissues is also > 95%, enabling physicochemical control over the combination ratios. This work illustrates a feasible paradigm to screen for optimal drug ratios, providing a high‐throughput approach for advancing combinatorial therapeutics.
- 5 November 2026
- Published by Wiley in Angewandte Chemie
Open AccessSelf‐Assembled Macrocyclic Nanocarriers for Rapid Ratiometric Loading and Dosing of Multidrug Combinations
Screening optimal drug combinations and dosing ratios is crucial for achieving and maximizing the synergistic therapeutic benefits in combined treatments. Traditional drug loading methods lack the precision to control drug ratios or involve complex technologies, failing to meet the demands of large‐scale screening in accuracy, convenience, and applicability. To address this, we developed a thermodynamically programmable macrocyclic nanoplatform based on amphiphilic calixarenes that overcomes the kinetic limitations on drug loading accuracy and reproducibility. This platform achieved precise drug loading and release with convenient tunability and broad‐spectrum applicability. For a series of drugs across various ratios, the actual loading ratio is > 95% consistent with the assigned values, and the consistency in delivery into cells and tumor tissues is also > 95%, enabling physicochemical control over the combination ratios. This work illustrates a feasible paradigm to screen for optimal drug ratios, providing a high‐throughput approach for advancing combinatorial therapeutics.
- Open Access
- 5 November 2026
- Published by Wiley in Angewandte Chemie International Edition
Self‐Assembled Macrocyclic Nanocarriers for Rapid Ratiometric Loading and Dosing of Multidrug Combinations
Screening optimal drug combinations and dosing ratios is crucial for achieving and maximizing the synergistic therapeutic benefits in combined treatments. Traditional drug loading methods lack the precision to control drug ratios or involve complex technologies, failing to meet the demands of large‐scale screening in accuracy, convenience, and applicability. To address this, we developed a thermodynamically programmable macrocyclic nanoplatform based on amphiphilic calixarenes that overcomes the kinetic limitations on drug loading accuracy and reproducibility. This platform achieved precise drug loading and release with convenient tunability and broad‐spectrum applicability. For a series of drugs across various ratios, the actual loading ratio is > 95% consistent with the assigned values, and the consistency in delivery into cells and tumor tissues is also > 95%, enabling physicochemical control over the combination ratios. This work illustrates a feasible paradigm to screen for optimal drug ratios, providing a high‐throughput approach for advancing combinatorial therapeutics.
- 5 November 2026
- Published by Wiley in Angewandte Chemie International Edition
Open AccessSelf‐Assembled Macrocyclic Nanocarriers for Rapid Ratiometric Loading and Dosing of Multidrug Combinations
Screening optimal drug combinations and dosing ratios is crucial for achieving and maximizing the synergistic therapeutic benefits in combined treatments. Traditional drug loading methods lack the precision to control drug ratios or involve complex technologies, failing to meet the demands of large‐scale screening in accuracy, convenience, and applicability. To address this, we developed a thermodynamically programmable macrocyclic nanoplatform based on amphiphilic calixarenes that overcomes the kinetic limitations on drug loading accuracy and reproducibility. This platform achieved precise drug loading and release with convenient tunability and broad‐spectrum applicability. For a series of drugs across various ratios, the actual loading ratio is > 95% consistent with the assigned values, and the consistency in delivery into cells and tumor tissues is also > 95%, enabling physicochemical control over the combination ratios. This work illustrates a feasible paradigm to screen for optimal drug ratios, providing a high‐throughput approach for advancing combinatorial therapeutics.
- 27 October 2026
- Published by Springer Nature in Nature Protocols
- p. 1-34
In situ assembly of peptides in living cells
The self-assembly of peptides into well-defined nanostructures represents a versatile strategy for developing biomedical agents. However, cellular internalization of pre-assembled peptide nanostructures is often hampered by insufficient uptake and low selectivity toward target cells, leading to off-target concerns and limited therapeutic efficacy. The past few years have witnessed the development of in situ assembly in living cells as a new endeavor for optimizing the performance of peptide assemblies. In situ assembly of peptides refers to intracellular assembling processes regulated by biocompatible stimuli, thereby enhancing peptide internalization and locally forming assemblies at target sites. Recently, we have developed strategies for establishing in situ assembly of peptides in living cells dictated by stimuli-responsive unnatural amino acids. Here we detail the procedure for developing in situ peptide assembly systems in living cells through incorporating stimuli-responsive unnatural amino acids. We present a thorough workflow encompassing peptide design and synthesis as well as the characterization of peptide responsiveness to glutathione or sulfatase. Self-assembly conditions are described for experiments in solution, in murine macrophage cells, human cervical carcinoma cells and murine breast cancer cells. The applications of in situ-formed peptide assemblies for subcellular targeting and cancer therapy in murine breast tumor-bearing BALB/c mice are also presented. The described methodology provides a robust platform for developing in situ-formed peptide assemblies and advancing the clinical translation of peptide-based supramolecular therapeutics. Performance of this Protocol requires expertise in peptide chemistry, materials engineering and biomedical engineering, taking an expected 92–115 d to complete.
- 27 October 2026
- Published by Springer Nature in Nature Protocols
- p. 1-34
In situ assembly of peptides in living cells
The self-assembly of peptides into well-defined nanostructures represents a versatile strategy for developing biomedical agents. However, cellular internalization of pre-assembled peptide nanostructures is often hampered by insufficient uptake and low selectivity toward target cells, leading to off-target concerns and limited therapeutic efficacy. The past few years have witnessed the development of in situ assembly in living cells as a new endeavor for optimizing the performance of peptide assemblies. In situ assembly of peptides refers to intracellular assembling processes regulated by biocompatible stimuli, thereby enhancing peptide internalization and locally forming assemblies at target sites. Recently, we have developed strategies for establishing in situ assembly of peptides in living cells dictated by stimuli-responsive unnatural amino acids. Here we detail the procedure for developing in situ peptide assembly systems in living cells through incorporating stimuli-responsive unnatural amino acids. We present a thorough workflow encompassing peptide design and synthesis as well as the characterization of peptide responsiveness to glutathione or sulfatase. Self-assembly conditions are described for experiments in solution, in murine macrophage cells, human cervical carcinoma cells and murine breast cancer cells. The applications of in situ-formed peptide assemblies for subcellular targeting and cancer therapy in murine breast tumor-bearing BALB/c mice are also presented. The described methodology provides a robust platform for developing in situ-formed peptide assemblies and advancing the clinical translation of peptide-based supramolecular therapeutics. Performance of this Protocol requires expertise in peptide chemistry, materials engineering and biomedical engineering, taking an expected 92–115 d to complete.
- 17 July 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (29) , 39695-39721
Stimuli-Responsive Synthetic Coacervates: Structural Design, Dynamics, and Functions
Liquid–liquid phase separation (LLPS), an interesting process in which a homogeneous solution demixes into solute-rich and solute-poor phases, serves as a ubiquitous mechanism for the formation of biomolecular condensates in living cells. Biomolecular condensates, also known as membraneless organelles, play critical roles in many fundamental physiological processes, including gene transcription, signal transduction, and stress responses. The intriguing LLPS phenomenon has inspired the development of artificial coacervates composed of biopolymers, synthetic macromolecules, or small molecules, driving exploration toward smart functional materials. For these synthetic coacervates, tailoring their structures and manipulating phase separation behaviors through external stimuli are essential to achieve precise functional control. This review summarizes recent advances in stimuli-responsive LLPS-based coacervates, focusing on structural design, formation mechanisms, stimuli-responsive characteristics, and functional applications. We thoroughly categorize the coacervates based on the diversity of stimulus sources used to regulate phase separation, with particular emphasis on the underlying molecular-level mechanisms. We highlight the applications of stimuli-responsive coacervates ranging from drug delivery and microreactors to biosensing. The prospects for stimuli-responsive LLPS systems for next-generation smart materials are also presented, aiming to elucidate their great potential in bridging the gap between the sophistication of biological coacervates and the performance of artificial smart materials.
- 17 July 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (29) , 39695-39721
Stimuli-Responsive Synthetic Coacervates: Structural Design, Dynamics, and Functions
Liquid–liquid phase separation (LLPS), an interesting process in which a homogeneous solution demixes into solute-rich and solute-poor phases, serves as a ubiquitous mechanism for the formation of biomolecular condensates in living cells. Biomolecular condensates, also known as membraneless organelles, play critical roles in many fundamental physiological processes, including gene transcription, signal transduction, and stress responses. The intriguing LLPS phenomenon has inspired the development of artificial coacervates composed of biopolymers, synthetic macromolecules, or small molecules, driving exploration toward smart functional materials. For these synthetic coacervates, tailoring their structures and manipulating phase separation behaviors through external stimuli are essential to achieve precise functional control. This review summarizes recent advances in stimuli-responsive LLPS-based coacervates, focusing on structural design, formation mechanisms, stimuli-responsive characteristics, and functional applications. We thoroughly categorize the coacervates based on the diversity of stimulus sources used to regulate phase separation, with particular emphasis on the underlying molecular-level mechanisms. We highlight the applications of stimuli-responsive coacervates ranging from drug delivery and microreactors to biosensing. The prospects for stimuli-responsive LLPS systems for next-generation smart materials are also presented, aiming to elucidate their great potential in bridging the gap between the sophistication of biological coacervates and the performance of artificial smart materials.
- 16 June 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 219, 561-573
A tumor-microenvironment-adaptive peptide-based nanophotothermal agent for synergistic photothermal–immunotherapy
- 16 June 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 219, 561-573
A tumor-microenvironment-adaptive peptide-based nanophotothermal agent for synergistic photothermal–immunotherapy
- 14 May 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (20) , 20532-20544
Protein Post-Translational Modification-Inspired Regulation of Peptide Coacervation in Living Cells for Pro-Necroptotic Kinase Delivery
Protein post-translational modifications (PTMs) play pivotal roles in modulating protein structures and functions in a complex biological environment; however, creation of artificial biomaterials resembling PTM processes remains challenging. Here, we report a PTM-inspired arginine methylation-regulated complex peptide coacervate R8-PD in living cells as delivery vehicles for pro-necroptotic protein receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and cancer therapy. Inspired by arginine methylation catalyzed by protein arginine methyltransferases (PRMTs), we create the peptide coacervate via complex liquid-liquid phase separation of an arginine-rich peptide R8 and charge-complementary poly(aspartic acid). The coacervate undergoes PRMT1-induced methylation, thus triggering coacervate dissolution and RIPK1 release. Cellular studies reveal the enhanced cellular uptake of the coacervate formulation RIPK1@R8-PD through caveolae-mediated endocytosis with dissolution occurring specifically in PRMT1-overexpressing cancer cells. Mechanistic studies directly illustrate activation of the necroptotic pathway involving phosphorylation of RIPK3 and mixed lineage kinase domain-like pseudokinase (MLKL) based on the PRMT1 overexpression-induced RIPK1 release from RIPK1@R8-PD, thus leading to cellular membrane permeabilization and death. Animal studies confirm that administration of the coacervate formulation significantly enhances the efficacy of tumor growth inhibition with an excellent biosafety profile. These findings in this study elucidate an innovative approach for the creation of PTM-inspired enzyme-responsive peptide coacervates to deliver proteins and necroptotic induction, thus providing a new strategy for drug delivery and cancer therapy in the future.
- 14 May 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (20) , 20532-20544
Protein Post-Translational Modification-Inspired Regulation of Peptide Coacervation in Living Cells for Pro-Necroptotic Kinase Delivery
Protein post-translational modifications (PTMs) play pivotal roles in modulating protein structures and functions in a complex biological environment; however, creation of artificial biomaterials resembling PTM processes remains challenging. Here, we report a PTM-inspired arginine methylation-regulated complex peptide coacervate R8-PD in living cells as delivery vehicles for pro-necroptotic protein receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and cancer therapy. Inspired by arginine methylation catalyzed by protein arginine methyltransferases (PRMTs), we create the peptide coacervate via complex liquid-liquid phase separation of an arginine-rich peptide R8 and charge-complementary poly(aspartic acid). The coacervate undergoes PRMT1-induced methylation, thus triggering coacervate dissolution and RIPK1 release. Cellular studies reveal the enhanced cellular uptake of the coacervate formulation RIPK1@R8-PD through caveolae-mediated endocytosis with dissolution occurring specifically in PRMT1-overexpressing cancer cells. Mechanistic studies directly illustrate activation of the necroptotic pathway involving phosphorylation of RIPK3 and mixed lineage kinase domain-like pseudokinase (MLKL) based on the PRMT1 overexpression-induced RIPK1 release from RIPK1@R8-PD, thus leading to cellular membrane permeabilization and death. Animal studies confirm that administration of the coacervate formulation significantly enhances the efficacy of tumor growth inhibition with an excellent biosafety profile. These findings in this study elucidate an innovative approach for the creation of PTM-inspired enzyme-responsive peptide coacervates to deliver proteins and necroptotic induction, thus providing a new strategy for drug delivery and cancer therapy in the future.
- Open Access
- 27 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (13) , eaeb2729
Clinically relevant stereochemistry reprograms amyloid proteome for aggregation cross-talk–conferred neuroprotection
The stereochemical diversity of Aβ42 in the brains of patients with Alzheimer’s disease (AD) is a clinically recognized but poorly understood phenomenon. A critical gap in our knowledge is how the complex mixture of these stereoisomers collectively influences the aggregation pathway and neurotoxicity of Aβ42 at the molecular level. Drawing from stereoproteome data from AD patient brain tissues and previous studies, we engineered a panel of stereoisomers to more simply simulate the stereochemical diversity of the AD marker Aβ42. We found that the coexistence of L-Aβ42 with specific D-isomers initiates a potent antagonistic effect, suppressing the formation of toxic fibrils. This stereochemically driven antagonism conferred notable neuroprotection, suggesting an endogenous protective mechanism. This proof-of-concept work elucidates at the molecular level that by regulating the stereochemical composition of Aβ, its inherent cellular protective antagonistic effect can be activated, providing unprecedented molecular basis for understanding the disease mechanism and subsequent possible clinical research.
- 27 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (13) , eaeb2729
Open AccessClinically relevant stereochemistry reprograms amyloid proteome for aggregation cross-talk–conferred neuroprotection
The stereochemical diversity of Aβ42 in the brains of patients with Alzheimer’s disease (AD) is a clinically recognized but poorly understood phenomenon. A critical gap in our knowledge is how the complex mixture of these stereoisomers collectively influences the aggregation pathway and neurotoxicity of Aβ42 at the molecular level. Drawing from stereoproteome data from AD patient brain tissues and previous studies, we engineered a panel of stereoisomers to more simply simulate the stereochemical diversity of the AD marker Aβ42. We found that the coexistence of L-Aβ42 with specific D-isomers initiates a potent antagonistic effect, suppressing the formation of toxic fibrils. This stereochemically driven antagonism conferred notable neuroprotection, suggesting an endogenous protective mechanism. This proof-of-concept work elucidates at the molecular level that by regulating the stereochemical composition of Aβ, its inherent cellular protective antagonistic effect can be activated, providing unprecedented molecular basis for understanding the disease mechanism and subsequent possible clinical research.
- Open Access
- 12 March 2026
- Published by Elsevier in SSRN Electronic Journal
A Tumor-Microenvironment-Adaptive Peptide-Based Nanophotothermal Agent for Synergistic Photothermal–Immunotherapy
Photothermal therapy (PTT) has attracted considerable attention in cancer treatment due to its noninvasive nature and lack of drug resistance. However, conventional photothermal agents often exhibit poor tumor accumulation, nonspecific thermal damage, and limited monotherapy efficacy, hindering their clinical translation. To overcome these constraints, we developed a tumor-microenvironment-adaptive peptide-based nano-photothermal agent (EIMSeO-IR783) founded on the principle of intermolecular coupling-induced supramolecular photothermal effects, and integrated it with a STING agonist for synergistic photothermal-immunotherapy. The nano-photothermal agent employs a redox-responsive peptide containing selenomethionine residues as a self-assembled skeleton, and realizing the transformation from nanoparticles to nanofibers through redox, thereby regulating the aggregation state of IR783 and inducing the formation of H-aggregates. These H-aggregates enhance non-radiative energy dissipation, leading to improved photothermal conversion efficiency and photostability. In the tumor microenvironment, overexpressed GSH drives adaptive morphological transformation, enabling precise in situ heat generation and improving tumor retention and ablation. Combined with the STING agonist, photothermal-induced immunogenic cell death promotes antigen release, dendritic cell maturation, and T-cell infiltration, eliciting a robust systemic immune response for synergistic photothermal-immunotherapy. This work proposes a tumor-microenvironment-guided strategy for constructing peptide-based photothermal systems, offering a new avenue for precise cancer therapy with controllable photothermal performance and immune synergy.
- 12 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA Tumor-Microenvironment-Adaptive Peptide-Based Nanophotothermal Agent for Synergistic Photothermal–Immunotherapy
Photothermal therapy (PTT) has attracted considerable attention in cancer treatment due to its noninvasive nature and lack of drug resistance. However, conventional photothermal agents often exhibit poor tumor accumulation, nonspecific thermal damage, and limited monotherapy efficacy, hindering their clinical translation. To overcome these constraints, we developed a tumor-microenvironment-adaptive peptide-based nano-photothermal agent (EIMSeO-IR783) founded on the principle of intermolecular coupling-induced supramolecular photothermal effects, and integrated it with a STING agonist for synergistic photothermal-immunotherapy. The nano-photothermal agent employs a redox-responsive peptide containing selenomethionine residues as a self-assembled skeleton, and realizing the transformation from nanoparticles to nanofibers through redox, thereby regulating the aggregation state of IR783 and inducing the formation of H-aggregates. These H-aggregates enhance non-radiative energy dissipation, leading to improved photothermal conversion efficiency and photostability. In the tumor microenvironment, overexpressed GSH drives adaptive morphological transformation, enabling precise in situ heat generation and improving tumor retention and ablation. Combined with the STING agonist, photothermal-induced immunogenic cell death promotes antigen release, dendritic cell maturation, and T-cell infiltration, eliciting a robust systemic immune response for synergistic photothermal-immunotherapy. This work proposes a tumor-microenvironment-guided strategy for constructing peptide-based photothermal systems, offering a new avenue for precise cancer therapy with controllable photothermal performance and immune synergy.
- 28 January 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 213, 678-690
Sulfatase-responsive phase-separating peptide coacervates target stress granules to reverse sorafenib resistance in hepatocellular carcinoma
- 28 January 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 213, 678-690
Sulfatase-responsive phase-separating peptide coacervates target stress granules to reverse sorafenib resistance in hepatocellular carcinoma